Research Progress and Challenges in the Use of TROP2-Targeted Antibody-Drug Conjugates for the Treatment of Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC), characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression, has long been associated with limited treatment targets, a high risk of recurrence and metastasis, and a poor prognosis. In recent ye...